According to people familiar with the matter, the European Medicines Agency (EMA) is expected to use it in early October.Pfizer(PFE.US)/BioNTech (BNTX.US)’s new crown vaccine booster decision.
It is reported that although the EU has not yet made a formal decision, many EU countries have already provided the new crown vaccine booster. Such an approach has certain legal risks.Pfizer/BioNTech signed 3 agreements to provide 2.4 billion doses of vaccine to the European Union. If the booster is approved by the European Medicines Agency, the EU may need more vaccines.
In addition, today, the U.S. Food and Drug Administration (FDA) stated that people 65 years of age and older, people at high risk of serious diseases, medical staff, and other people at high risk of exposure to COVID-19 at work can be vaccinatedPfizer/BioNTech’s new crown vaccine booster. This emergency approval is in line with the recommendations made by the FDA advisers last week, but is narrower than the comprehensive approvals sought by Pfizer and BioNTech.
Pfizer and BioNTech did not comment on this. As of press time, before the US stock market on Thursday, Pfizer rose 0.68%, BioNTech rose 0.67%.
(Source: Zhitong Finance Network)
Article source: Zhitong Finance Network
Editor in charge: DF551
Original title: European Medicines Agency may decide in early October whether to use Pfizer (PFE.US)/BioNTech (BNTX.US) new crown vaccine booster
Solemnly declare: The purpose of this information released by Oriental Fortune.com is to spread more information and has nothing to do with this stand.
report
Scan the QR code to follow
Oriental Wealth Official Website WeChat
.